ArticleFrontiers in cardiovascular medicine2025
Impact of sarcopenia on ventricular remodelling following coronary artery bypass grafting in elderly patients with coronary heart disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between sarcopenia and ventricular remodelling after coronary artery bypass grafting (CABG) in elderly patients with coronary heart disease (CHD). Methods: A total of 135 elderly patients with CHD admitted to hospital between February 2021 and May 2023 were prospectively selected. According to whether ventricular remodelling occurred during the follow-up period, patients were divided into an occurrence group and a non-occurrence group. Results: The incidence of ventricular remodelling after CABG in elderly patients with CHD was 23.70% (32/135). Significant differences between the two groups were observed in smoking history, diabetes history, prevalence of sarcopenia, degree of preoperative coronary stenosis, levels of lipoprotein (a) ([Lp(a)]), uric acid (UA), protease-activated receptor 2 (PAR2), monocyte-to-HDL ratio (MHR), and suspended red blood cell input ( Conclusion: Sarcopenia is a risk factor affecting ventricular remodelling after CABG in elderly patients and shows strong predictive efficacy in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.